Groningen, The Netherlands – 24 January 2025 – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today announced the expansion of an ongoing formulation development program with a returning undisclosed global Top 10 pharmaceutical company. The project builds on a previously successful collaboration using InnoCore’s proprietary SynBiosys® technology and reflects the Company’s strategic growth plan to expand its work with biologics and peptide LAI dosage forms.
The expanded agreement will focus on the development of sustained-release formulations of a peptide candidate. Successful development of such formulations will significantly strengthen the competitive position of the company’s product portfolio in this field. The focus for the project reinforces InnoCore’s position as a trusted partner in advanced drug delivery innovation and also validates InnoCore’s proprietary SynBiosys®, a best-in-class, biodegradable polymeric injectable delivery system.
SynBioys® is capable of overcoming the well-known challenges associated with formulating fragile biomolecules into tunable, scalable and stable long-acting dosage forms. The technology has a proven ability to deliver high-value, patient-friendly, and commercially scalable LAI products. It’s unique, customizable properties enable InnoCore’s partners to tailor release kinetics, maintain molecular integrity, and extend product lifecycles, addressing the pharmaceutical industry’s increasing demand for sustained-release biologic and peptide therapies.
Martin Bakker, CBO at InnoCore Pharmaceuticals, said:
“We’re proud to deepen our partnership with one of our existing partners in the global pharmaceutical industry. This expansion reflects both the customer’s confidence in our scientific expertise and the unparalleled performance of our SynBiosys® platform. Together, we’re creating advanced LAI formulations that will help improve therapeutic outcomes, enhance patient convenience, and unlock new commercial opportunities for biologics and peptides.”
With more than 20 years of formulation and process development expertise, InnoCore continues to strengthen its reputation as the partner of choice for complex drug delivery challenges. The Company’s state-of-the-art facilities in Groningen, combined with its multidisciplinary scientific team, enable the seamless translation of challenging APIs into long-acting, high-quality products ready for clinical and commercial scale-up.
-Ends-
For more information, please contact:
Notes to Editors
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance.
For more information, please see: www.innocorepharma.com.